Targeting Cancer Cells with Dendrimers  by Sampathkumar, Srinivasa-Gopalan & Yarema, Kevin J.
Chemistry & Biology, Vol. 12, 5–13, January, 2005, ©2005 Elsevier Ltd All rights reserved. DOI 10.1016/j.chembiol.2004.12.007
PreviewsTargeting Cancer Cells
with Dendrimers
Bifunctional PAMAM-based dendrimers that selec-
tively target cancer cells are described in this issue
of Chemistry & Biology [1]. The targeting moiety for
folate receptor is complexed to an imaging or thera-
peutic agent by a DNA “zipper”—a versatile strategy
to create libraries of novel drugs.
Dendritric, or “tree-like,” structures widely occur in na-
ture [2]. The dendritic network of hairs found on the
Gecko foot that allows amazingly strong attachment to
many types of surfaces due to van der Walls forces
provides a dramatic example of dendrimers in action
[3]. Clearly, synthetic methods to create dendritic mole-
cules in the laboratory have been of great interest for
many decades, for both scientific and practical reasons.
A lack of facile synthetic approaches to create these
molecules, however, hampered development of this
field until approximately 25 years ago. In 1978, Vögtle’s
group reported the innovative “cascade” methodology
for the synthesis of dendrimer-like molecules [2, 4], and
since then, the intense efforts underway to create these
macromolecules have followed two major strategies.
First, in the divergent method, the growth of a dendron
(a molecular tree) originates from a core site, or root;
conversely, in the convergent growth process, synthe-
sis proceeds from what will become the dendron mo-
lecular surface (i.e., from the leaves of the trees) inward
to a reactive focal point at the root. Together, these ef-
forts have resulted in the synthesis of over 100 compo-
sitionally different dendrimer families [5].
Dendrimers, being chemical entities with biological
properties, provide an outstanding example of the
close relationship between these two fields. As men-
tioned, these molecules were initially inspired by na-
ture. The efforts of synthetic chemists to create mimics,
however, have resulted in dendritic clusters with a wide
variety of properties and potential applications, many
of which are now distinctly nonbiological. For example,
organometallic dendrimers are finding uses as quan-
tum dots, as industrial catalysts, and in electronics [5,
6]. Other families of dendrimers remain firmly at the in-
tersection of chemistry and biology. For instance, these
molecules can be constructed to closely resemble pro-
teins, as they are of comparable size and can be en-
dowed with similar biologically compatible surface
properties. Their surfaces, however, can also be given
a significant repertoire of tunable characteristics not
found on natural proteins; this feature has greatly pro-
pelled efforts toward the development of practical ap-
plications for these molecules. In particular, the ability
of a dendrimer to be functionalized with far more sur-
face groups than a protein of comparable size has
given impetus to their widespread use as drug deliv-
ery vehicles.It is no secret that drug design and delivery consti-
tutes a formidable biomedical challenge. A potential
drug must first selectively recognize and bind to a mo-
lecular target, then trigger an appropriate biological re-
sponse, and all the while possess pharmacological
properties that render it “drug-like.” In some cases, na-
ture has supplied appropriate small molecules—such
as aspirin or penicillin—that can be used directly as
drugs. Meanwhile, rational design of small-molecule
drugs has, in general, proven to be remarkably intracta-
ble, especially when confronting complex diseases like
cancer. Cancer epitomizes the challenges confronting
drug delivery efforts: An anticancer drug must be able
to seek out subtle changes that distinguish a trans-
formed cell from the other 200 or so types of healthy
cells found in the body and then provide a sufficiently
high dose of a toxic agent to kill the cell. Not surpris-
ingly, single small molecules often function poorly at
these tasks, thereby requiring the use of therapeutic
cocktails in clinical practice. Proteins have shown
promise in combining aspects of the different biofunc-
tions expected of an anticancer drug. Specifically,
monoclonal antibodies raised against tumor-associ-
ated antigens provide selective targeting of cancer
cells; when conjugated to toxic agents, they can also
kill the target cell. In many cases, however, antibody-
based conjugates struggle to provide sufficiently high
levels of drug. To illustrate this, consider that a cancer-
specific antibody might gain access to 50,000 binding
sites per cell. The widely used anticancer drug cisplatin
requires internalization of at least ten times this level for
efficacy. Consequently, antibody conjugates generally
exclude small-molecule drugs and are limited to toxins,
such as ricin, where the catalytic activity of this ribo-
some-inactivating enzyme allows a single molecule to
kill a cell [7]. Of course, conjugation of two proteins
(ricin and the antibody) does nothing to improve the
poor pharmacological properties of either entity alone,
and it is not surprising that after two decades of investi-
gation such strategies remain far from widespread
practical use.
The cancer cell-targeting approach described in this
issue by Choi and coworkers [1] is reminiscent of the
antibody-toxin/immunoconjugate strategy where dis-
tinct, but linked, entities are used to first recognize and
bind and then subsequently modify a cancer cell. The
current investigators’ strategy, however, has great po-
tential to improve on both the “targeting” and “pay-
load” capsules by replacing the protein subunits with
dendritic PAMAM-based clusters [8] that are covalently
conjugated to complementary oligodeoxynucleotides
as shown schematically in Figure 1. This approach
takes advantage of the already-established biocompat-
ibility of DNA and PAMAM, which has often been used
to introduce DNA into cells for gene delivery, except
that now DNA is used as a zipper between a folate-
derivatized targeting capsule and its payload, an im-
aging agent (FITC) in this case. It also exploits the facile
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6Figure 1. DNA-Dendrimer Conjugates as Po-
tential Cancer Targeting Imaging Agents or
Therapeutics
Differentially functionalized dendrimers co-
valently conjugated to complementary
deoxy-oligonucleotides can readily form du-
plex combinatorial nanoclusters that pos-
sess cancer cell-specific ligands hybridized
to an imaging agent or drug. Cell-specific
target ligands (e.g., folic acid) are appended
to dendrimer A, and dendrimer B is conju-
gated with an imaging agent (e.g., fluores-
cein) or drug.duplex DNA formation for the generation of hybrid na- a
noclusters, thus circumventing the tedious synthesis of t
multiply-functionalized dendrimers. The current work is e
limited to “proof-of-concept” experiments, and a long e
road lies ahead to actual use at the clinical level. For l
example, potential obstacles include nonspecific cellu- m
lar uptake of PAMAM-based cationic dendrimers, mem- w
brane destabilization, and toxicity [6]. These limitations, e
however, are already being addressed by further chemi- d
cal modification of the dendrimer surface [9] or substi- i
tution with anionic, polyester dendrimeric clusters [10], n
leaving viable the exciting possibility that this tech-
nique can be applied to many types of cancer by mix- S
ing-and-matching various targeting (“A” in Figure 1) a
and modifying (“B”) clusters. D
In the future, bifunctional dendritic molecules can be T
readily adapted to exploit surface markers other than B
the canonical folate receptor [9, 11] or the numerous
approaches that target tumor-associated antigens [12]. S
One area of rapidly expanding investigation is the ab-
normal glycosylation associated with the cancer cells.
Dendrimeric scaffolds provide a unique platform to
control the multimeric carbohydrate presentation
needed to enact the “cluster glycoside effect” [13, 14],
which is crucial for targeting diseased tissues in malig-
nant diseases [2, 6]. Finally, additional “chemical biol-
ogy” strategies can come into play, such as the expres-
sion of metabolic analogs into sialic acids, sugars that
are often overexpressed on cancer cells to provide a
“chemical handle” for targeted delivery of a second
agent [15]. In this case, the dendritic presentation of
complementary chemical functional group could en-
hance binding of the second agent to the cell surface.
To complement the targeting cluster and complete
the activity of a DNA-assembled PAMAM cluster, the
action modules represented by “Dendrimer B” (in Fig-
1
ure 1) fall into two main categories; one category con-
sists of imaging agents such as the FITC conjugate 1
used in the current cell-based work. A natural extension
1of this approach will be to substitute gadolinium chela-
1tors for use as MRI contrast agents [16] for the detec-
tion and diagnosis of cancer. The actual killing of can-
1
cer cells entails the complicated process of drug
uptake followed by release of the drug into the cyto- 1
plasm or nucleus and is clearly a more demanding pro-
1cess than simple cell labeling. Many options are avail-ble to ensure successful delivery of the prodrug into
he cell. These include activation by low pH found in
ndosomal vesicles, installation of enzyme-cleavable
ster linkages onto the drug, disulfide bonds that are
iberated in the reducing environment of the endoplas-
ic reticulum, or sensitivity to ultrasound. Clearly, a
ealth of different forms of bifunctional clusters can be
nvisioned. The ability to design and produce arrays of
endrimers assembled by DNA zippers constitutes an
mportant step in the development of these versatile
anoclusters as imaging and therapeutic agents.
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